Other current assets (Details) - USD ($) $ in Thousands |
Jul. 31, 2020 |
Jun. 30, 2020 |
Dec. 31, 2019 |
|---|---|---|---|
| Other current assets | |||
| Corporate tax receivable | $ 26,746 | $ 19,284 | |
| Prepayments | 7,903 | 8,395 | |
| Clinical materials | 1,521 | 1,459 | |
| Other current assets | 2,929 | 1,809 | |
| Total | $ 39,099 | $ 30,947 | |
| Research & Development Tax Credits | |||
| Other current assets | |||
| Corporate tax receivable | $ 18,700 |
| X | ||||||||||
- Definition Clinical materials for use in research and development with alternative future use expected to be consumed within one year or the normal operating cycle. No definition available.
|
| X | ||||||||||
- Definition Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of current assets classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|